Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening, and welcome to Dyadic International's Q3 2025 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference call is being recorded today, November 12, 2025. I would now like to turn the call over to Ms. Peng Rawson, Dyadic's Chief Financial Officer. Please go ahead. Thank you. Good evening and welcome everyone to Dyadic's Q3 2025 conference call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the quarter ended September 30, 2025. You may access our release and form 10Q and their investor session of the company's website at dyadic.com. On today's call, our president and chief operating officer, Joe Hazleton, will give a review of our Q3 2025 business and corporate highlights and provide a commentary on the strategic direction of the business. Our CEO, Mark Emelfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we'll hold a brief question and answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involves risks and uncertainties and other factors that could cause dyadic actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forebooking statements, whether because of new information for future events or otherwise. Participants are directed to the risk factors set forth in DIAT-X reports filed with th...